[Intravitreal bevacizumab for chronic central serous chorioretinopathy].

Central serous chorioretinopathy (CSCR) can lead to permanent visual loss in chronic cases. We report on a 57-year-old female patient with persistent findings over 6 months despite conservative therapy. A single intravitreal injection of bevacizumab led to a rapid morphologic and functional restitution without relapse or complication during the 19 weeks period after injection. Intravitreal injection of bevacizumab could be a therapeutic option for the treatment of chronic CSCR, however the results of appropriate studies must be awaited before it can be introduced into routine use.